PREVALENCE AND SEVERITY OF AKATHISIA IN PATIENTS ON CLOZAPINE
PREVALENCE AND SEVERITY OF AKATHISIA IN PATIENTS ON CLOZAPINE
复制标题
DOI：
10.1016/0006-3223(91)90329-k
复制
发表时间：
1991-06-15
影响因子：
10.6
通讯作者：
COLE, JO
中科院分区：
文献类型：
--
作者：
COHEN, BM;KECK, PE;COLE, JO
据报道，非典型抗精神病药物氯氮平具有独特的治疗效果，并产生最小的锥体外系副作用。然而，在一项盲法调查中，观察到在接受氯氮平治疗的患者和接受标准抗精神病药物治疗的患者中，静坐症的患病率和严重程度相似。此外，与标准抗精神病药物一样，接受氯氮平治疗的患者出现静坐障碍与较差的总体临床结果相关。结果表明，静坐症可能是所有抗精神病药物的共同副作用，静坐症可能是由不同于这些药物的其他运动效应的机制产生的，并且接受氯氮平治疗的患者和接受标准抗精神病药物治疗的患者一样，应该监测静坐症。
The atypical antipsychotic clozapine is reported to have unique therapeutic effects and to produce minimal extrapyramidal side effects. However, in a blind survey, akathisia was observed to be similar in prevalence and severity in patients treated with clozapine and those receiving standard neuroleptic antipsychotic drugs. In addition, as with standard antipsychotic drugs, the presence of akathisia in patients receiving clozapine was associated with a worse overall clinical outcome. The results suggest that akathisia may be a common side effect of all antipsychotic drugs, that akathisia may be produced by a mechanism distinct from other locomotor effects of these medications, and that patients receiving clozapine, like patients receiving standard antipsychotic drugs, should be monitored for akathisia.